Phase I Open-Label Study of Fostamatinib, a SYK Inhibitor, in Patients With Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Fostamatinib (Primary)
- Indications Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 10 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2023 Planned End Date changed from 26 Mar 2023 to 30 Apr 2025.
- 04 Apr 2023 Planned primary completion date changed from 26 Mar 2023 to 30 Apr 2025.